Journalism of Courage
Premium
This is an archive article published on March 8, 2013
Bayer to approach HC against order on Nexavar
Bayer holds the patent right for Nexavar in India until 2020 and it will continue to defend its intellectual property rights within the Indian legal system,the spokesperson said.
Bayer has said it will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to Indias Natco Pharma to make and sell a low-cost generic of the German drug majors patented cancer drug Nexavar.
Bayer will not accept a ruling by the Intellectual Property Appellate Board IPAB in Chennai on Monday,upholding the compulsory licence granted on March 9 last year and it will appeal against the patent office order at the high court in Mumbai,a spokesperson said.
Bayer holds the patent right for Nexavar in India until 2020 and it will continue to defend its intellectual property rights within the Indian legal system,the spokesperson said.
The IPAB ruling was in response to a petition filed by the German drug maker on May 4 last year seeking to overturn the compulsory licence issued by the Controller General of Patents,Designs and Trademarks to the Hyderabad-based Natco Pharma. In an initial judgement,the IPAB had in September last year dismissed a petition by Bayer to stay the compulsory licence.
Advertisement
Loading Recommendations...
Live Blog